Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Institute for Human Genetics, University of California, San Francisco, CA, USA.
Neurotherapeutics. 2018 Jan;15(1):126-134. doi: 10.1007/s13311-017-0587-y.
Multiple sclerosis (MS) is the prototypic complex disease, in which both genes and the environment contribute to its pathogenesis. To date, > 200 independent loci across the genome have been associated with MS risk. However, these only explain a fraction of the total phenotypic variance, suggesting the possible presence of additional genetic factors, and, most likely, also environmental factors. New DNA sequencing technologies have enabled the sequencing of all kinds of microorganisms, including those living in and around humans (i.e., microbiomes). The study of bacterial populations inhabiting the gut is of particular interest in autoimmune diseases owing to their key role in shaping immune responses. In this review, we address the potential crosstalk between B cells and the gut microbiota, a relevant scenario in light of recently approved anti-B-cell therapies for MS. In addition, we review recent efforts to characterize the gut microbiome in patients with MS and discuss potential challenges and future opportunities. Finally, we describe the international MS microbiome study, a multicenter effort to study a large population of patients with MS and their healthy household partners to define the core MS microbiome, how it is shaped by disease-modifying therapies, and to explore potential therapeutic interventions.
多发性硬化症(MS)是一种典型的复杂疾病,其发病机制既与基因有关,也与环境有关。迄今为止,已经在基因组中发现了超过 200 个独立的与 MS 风险相关的位点。然而,这些只能解释总表型变异的一小部分,这表明可能存在其他遗传因素,而且很可能还有环境因素。新的 DNA 测序技术使对各种微生物的测序成为可能,包括生活在人类体内和周围的微生物(即微生物组)。由于肠道细菌在塑造免疫反应方面发挥着关键作用,因此研究居住在肠道内的细菌种群在自身免疫性疾病中具有特别的意义。在这篇综述中,我们讨论了 B 细胞与肠道微生物群之间潜在的相互作用,鉴于最近批准的用于 MS 的抗 B 细胞疗法,这是一个相关的场景。此外,我们还回顾了最近在 MS 患者中对肠道微生物群进行特征描述的努力,并讨论了潜在的挑战和未来的机会。最后,我们描述了国际 MS 微生物组研究,这是一项多中心研究,旨在研究大量 MS 患者及其健康的家庭伴侣,以确定 MS 的核心微生物组,研究其如何受疾病修正疗法的影响,并探索潜在的治疗干预措施。